Trial reportEuropean journal of nuclear medicine and molecular imaging2011
FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
Trial report in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Axillary ultrasound for prediction of response to neoadjuvant therapy in the context of surgical strategies to axillary dissection in primary breast cancer: a systematic review of the current literature.Archives of gynecology and obstetrics · 2020Pooled it
- Impact of partial-volume correction in oncological PET studies: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2017Pooled it
- Neoadjuvant chemotherapy of breast cancer with pirarubicin versus epirubicin in combination with cyclophosphamide and docetaxel.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Trial
- TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015Trial
- Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.European journal of nuclear medicine and molecular imaging · 2014Trial
- [La Radiologia medica · 2026Review
- Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- A review of the association between baseline [ 18 F] fluorodeoxyglucose uptake and axillary pathological complete response in node-positive breast cancer patients: focus on clinical subtypes.Nuclear medicine communications · 2025Review
- Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023Review
- Article
- Novel applications of molecular imaging to guide breast cancer therapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Value ofEJNMMI research · 2021Article
- Update on Quantitative Imaging for Predicting and Assessing Response in Oncology.Seminars in nuclear medicine · 2020Review
- Subtype-GuidedThe oncologist · 2020Article
- Additional value ofCancer imaging : the official publication of the International Cancer Imaging Society · 2017Article
- Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials.Breast cancer research : BCR · 2016Review
- ¹⁸F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016Review
- Article
- Positron Emission Tomography in Breast Cancer.Diagnostics (Basel, Switzerland) · 2015Review
- Sequential (18)F-FDG PET/CT for early prediction of complete pathological response in breast and axilla during neoadjuvant chemotherapy.European journal of nuclear medicine and molecular imaging · 2014Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRegional axillary lymph node status has remained the single most independent variable to predict prognosis both in terms of disease recurrence and survival. This study aimed to prospectively assess sequential [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) findings as early predictors of axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
methodsImages were acquired with a PET/CT scanner in 52 patients after administration of FDG (5 MBq/kg) at baseline and after the first, second, third and sixth course of chemotherapy before surgery. Clinical examination and ultrasound (US) were used to assess the size of axillary nodes. Decrease in the standardized uptake value (SUV) with PET corrected or not for partial volume effects was compared to the pathological response.
resultsThe sensitivity, specificity and accuracy of axillary node staging was higher with PET (75, 87 and 80%) than with US (50, 83 and 65%), and even more so when PET images were corrected for partial volume effects (86, 83 and 84%). While FDG uptake did not vary much in non-responders, as confirmed by histopathological analysis, it markedly decreased to baseline levels in responders (p < 10(-5)). Fifty per cent of baseline SUV was considered the best cutoff value to distinguish responders from non-responders. The sensitivity, specificity, negative predictive value and accuracy of FDG PET after one course of chemotherapy were, respectively, 96, 75, 95 and 84%.
conclusionThe pathological status of regional axillary lymph nodes in stage II and III breast cancer patients could be accurately predicted after one course of neoadjuvant chemotherapy based on FDG PET images.
Indexed as
Identifiers
21308372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.